The extravasated leucocytes were counted with a flow cytometer (Epics Elite; Beckman Coulter Inc., Hialeah, FL, USA). Expression of CD11b activation epitope on extravasated neutrophils.  Extravasated neutrophils, collected from the 14-h skin blister,

were analysed for the expression BGB324 price of CD11b activation epitope following labelling with 20 μl of phycoerythrin (PE)-conjugated antibody, clone CBRM1/5 (BioLegend, San Diego, CA, USA) or the IgG1 isotype control. The expression of CD11b activation epitope on peripheral circulating neutrophils was analysed in parallel following haemolysis of the erythrocytes and washing in phosphate-buffered saline (PBS) as described later. After 30 min of labelling on ice, the cells were washed in PBS, and the expression of CD11b was analysed by a flow cytometer (Navios; Beckman Coulter Inc.). Measurement of soluble mediators.  Soluble mediators in the skin chamber fluid and in serum were measured with a 26-plex Milliplex human cytokine/chemokine kit according to the standardized protocol provided by the manufacturer (Millipore Corp, St. Charles, MO, USA). The skin chamber fluid was diluted eight times in total before assessment. The concentrations of MCP-1 and IL-8 in the skin chamber fluid were out of range for Milliplex measurement and were,

therefore, further assessed with enzyme-linked immunosorbent assay (ELISA) (Quantikine immunoassay; R&D systems, Abingdon, UK) following PD0325901 mw 40 and 80 times dilution, respectively. In addition, IL-8 was analysed in the original skin blister fluid after 10 times dilution. The concentration of the terminal complement complex (TCC) was analysed by a commercial kit (Hycult Biotech, Uden, the Netherlands). All measurements were performed according to laboratory guidelines provided by the manufacturers. CD11b expression following incubation with skin chamber fluid or recombinant IL-8.  Peripheral blood from two healthy donors was drawn in tubes containing 0.129 m Na citrate (Vacutainer; Becton Dickinson, Plymouth, UK). The blood was portioned in 200 μl per tube, and the erythrocytes were haemolysed by

an isotonic solution [154 mm NH4CL, 10 mm KHCO3 and 0.1 mm EDTA, pH 7.2]. The tubes were centrifuged, and the leucocytes were washed with PBS and then incubated RVX-208 with 180 μl of skin chamber fluid or the corresponding serum for 30 min on 37 °C. Chamber fluid and serum from 10 donors were assessed individually (n = 10) at two occasions with different blood donors. The skin chamber fluids were diluted with PBS 1:2 in the aspiration step, and for comparison between serum and blister fluid, the serum samples were also diluted 1:2 in PBS before incubation. Incubation with RPMI containing 5% human serum albumin (HSA) was used as a negative control (n = 7), and leucocytes incubated with 100 ng/ml IL-8 (R&D Systems Inc., Minneapolis, MN, USA) was used as a positive control (n = 8), both at 37 °C. In addition, one control was incubated on ice with RPMI and 5% HSA (n = 7).